Ariel Dora Stern

Harvard Business School

Associate Professor

Morgan Hall 433

Harvard Business School

Boston, MA MASSACHUSETTS 02163

United States

http://www.hbs.edu/astern

SCHOLARLY PAPERS

11

DOWNLOADS

1,441

SSRN CITATIONS
Rank 16,143

SSRN RANKINGS

Top 16,143

in Total Papers Citations

76

CROSSREF CITATIONS

11

Scholarly Papers (11)

1.

The Impact of the Entry of Biosimilars: Evidence from Europe

Morton, Fiona M. Scott, Ariel Dora Stern, and Scott Stern. "The impact of the entry of biosimilars: evidence from Europe." Review of Industrial Organization 53, no. 1 (2018): 173-210.
Number of pages: 71 Posted: 24 Jul 2016 Last Revised: 04 May 2019
Fiona M. Scott Morton, Ariel Dora Stern and Scott Stern
Yale School of Management, Harvard Business School and Massachusetts Institute of Technology (MIT) - Sloan School of Management
Downloads 435 (123,800)
Citation 10

Abstract:

Loading...

Biosimilars; Biologics; Pharmaceutical Competition; Health Care Spending; Innovation

2.

Responding Strategically to Competitors' Failures: Evidence from Medical Device Recalls & New Product Submissions

Harvard Business School Working Paper 19-028 , Georgetown McDonough School of Business Research Paper No. 3251630
Number of pages: 35 Posted: 12 Oct 2018 Last Revised: 19 May 2022
George Ball, Jeffrey T. Macher and Ariel Dora Stern
Operations and Decision Technologies Dept, Kelley School of Business, Indiana University, Georgetown University - McDonough School of Business and Harvard Business School
Downloads 380 (145,353)
Citation 3

Abstract:

Loading...

3.

How Important is Editorial Gatekeeping? Evidence from Top Biomedical Journals

Harvard Business School Technology & Operations Mgt. Unit Working Paper No. 22-011, Harvard Business School Entrepreneurial Management Working Paper No. 22-011
Number of pages: 45 Posted: 12 Jul 2021 Last Revised: 16 Feb 2023
Joshua Krieger, Kyle Myers and Ariel Dora Stern
Harvard University - Business School (HBS), Harvard University - Technology & Operations Management Unit and Harvard Business School
Downloads 169 (321,784)
Citation 1

Abstract:

Loading...

4.

Pioneer (Dis-)advantages in Markets for Technology

Harvard Business School Working Paper No. 19-043
Number of pages: 42 Posted: 01 May 2019 Last Revised: 18 Mar 2020
Moritz Fischer, Joachim Henkel and Ariel Dora Stern
Technische Universität München (TUM), TUM School of Management - Technical University of Munich (TUM) and Harvard Business School
Downloads 163 (332,012)

Abstract:

Loading...

First-Mover Advantages, Markets for Technology, M&A, Technology Acquisition, Medical Devices

5.

Innovation Under Regulatory Uncertainty: Evidence from Medical Technology

Stern, A.D., Innovation under Regulatory Uncertainty: Evidence from Medical Technology, Journal of Public Economics. Final version published online: 06-Dec-2016. DOI information: 10.1016/j.jpubeco.2016.11.010, Journal of Public Economics, Vol. 145, 2017
Number of pages: 20 Posted: 17 Oct 2016 Last Revised: 13 Aug 2018
Ariel Dora Stern
Harvard Business School
Downloads 94 (503,030)
Citation 12

Abstract:

Loading...

Regulation, Innovation, FDA, Medical Devices

6.

Physician Beliefs and Patient Preferences: A New Look at Regional Variation in Health Care Spending

NBER Working Paper No. w19320
Number of pages: 64 Posted: 17 Aug 2013 Last Revised: 17 Apr 2022
Harvard University - Department of Economics, Dartmouth College - Department of Economics, Harvard Business School and Geisel School of Medicine at Dartmouth
Downloads 75 (576,502)
Citation 47

Abstract:

Loading...

Regulatory Incentives for Innovation: The FDA's Breakthrough Therapy Designation

HKS Working Paper No. RWP22-024
Number of pages: 88 Posted: 09 Dec 2022 Last Revised: 31 Jan 2023
Harvard University - Harvard Kennedy School (HKS), UCLA Anderson, U.S. Food and Drug Administration and Harvard Business School
Downloads 51 (714,401)

Abstract:

Loading...

Regulatory Incentives for Innovation: The Fda's Breakthrough Therapy Designation

NBER Working Paper No. w30712
Number of pages: 89 Posted: 06 Dec 2022 Last Revised: 02 Jun 2023
Harvard University - Harvard Kennedy School (HKS), UCLA Anderson, U.S. Food and Drug Administration and Harvard Business School
Downloads 5 (1,125,362)
Citation 2
  • Add to Cart

Abstract:

Loading...

8.

Characterizing the Drug Development Pipeline for Precision Medicines

NBER Working Paper No. w24026
Number of pages: 70 Posted: 20 Nov 2017 Last Revised: 24 Feb 2023
Amitabh Chandra, Craig L. Garthwaite and Ariel Dora Stern
Harvard University - Harvard Kennedy School (HKS), Northwestern University - Department of Management & Strategy and Harvard Business School
Downloads 39 (779,193)
Citation 3

Abstract:

Loading...

9.

Which Markets (Don'T) Drive Pharmaceutical Innovation? Evidence from U.S. Medicaid Expansions

NBER Working Paper No. w28755
Number of pages: 47 Posted: 10 May 2021 Last Revised: 26 Jan 2023
Craig Garthwaite, Rebecca Sachs and Ariel Dora Stern
Northwestern University, George Washington University - Law School and Harvard Business School
Downloads 19 (951,173)

Abstract:

Loading...

10.

The Regulation of Medical Ai: Policy Approaches, Data, and Innovation Incentives

NBER Working Paper No. w30639
Number of pages: 26 Posted: 05 Dec 2022 Last Revised: 14 Apr 2023
Ariel Dora Stern
Harvard Business School
Downloads 11 (1,030,872)
  • Add to Cart

Abstract:

Loading...

11.

Germany’s Digital Health Reforms in the COVID-19 Era: Lessons and Opportunities for Other Countries

npj Digit. Med. 3, 94 (2020). https://doi.org/10.1038/s41746-020-0306-7
Posted: 09 Jul 2021
Sara Gerke, Ariel Dora Stern and Timo Minssen
Pennsylvania State University, Dickinson Law, Harvard Business School and University of Copenhagen - Centre for Advanced Studies in Biomedical Innovation Law (CeBIL) - Faculty of Law

Abstract:

Loading...

Digital Health, Germany, Apps, Digital Healthcare Act